Background

The development of psychiatric medications using hallucinogens has been hindered by strict regulatory barriers for decades. Since the enactment of the Controlled Substances Act in the United States in the 1970s, substances such as psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) have been classified as Schedule I drugs, deemed to have a high potential for abuse and no accepted medical value. As the number of refractory patients who do not respond to existing treatments surges, academia has begun to focus again on the binding of these substances to serotonin 2A (5-HT2A) receptors and their neuroplasticity-promoting effects.

As clinical research progresses, structural conflicts with existing drug approval standards have become prominent. Patients administered psychedelics inevitably experience intense perceptual distortions and emotional elevation. This characteristic leads to functional unblinding, where the placebo group and the test drug group are clearly distinguishable immediately after administration. As most participants realized they were taking the investigational drug, this flaw was followed by the distortion of therapeutic effects due to expectation bias.

The problem of difficulty in quantifying the scope of psychotherapeutic interventions associated with drug administration persisted. The U.S. Food and Drug Administration (FDA) is a regulatory agency that verifies the pharmacological safety and efficacy of chemical molecules, but it lacked the authority to review or approve psychotherapy techniques as medical practices. The structure is such that verifying the pure pharmacological effect faces difficulties due to data bias arising from the subjective competence of counselors. The incident in 2024, when an external advisory committee issued a negative evaluation of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), was a decisive moment that revealed the limitations of traditional clinical design. This is interpreted as the background for the need for new review criteria to incorporate hallucinogens into the regular medical system.

Key Findings

This analysis published in the New England Journal of Medicine (NEJM) systematically outlines the key principles proposed to fill the regulatory gap surrounding the evaluation of psychedelic drugs. The new standards discourage the use of simple saline controls in clinical trial designs and mandate dose-response designs. In the case of psilocybin trials, the policy encourages constructing multi-dose groups by administering a non-hallucinogenic microdose (1 mg), an intermediate dose (10 mg), and a target therapeutic dose (25 mg). The introduction of an 'active placebo' that induces similar physiological responses has also been included in the recommendation list.

A remote independent evaluator system will be introduced to prevent evaluation bias. This method involves independent psychiatrists, who were not present during the patient's hallucinogenic experience, scoring scales such as the Montgomery-Åsberg Depression Rating Scale (MADRS) via video interviews. This measure aims to mitigate the impact of emotional bonding that arises during medication sessions on evaluation metrics. Analysis suggests that applying this regulatory framework could reduce the overestimation of effect size due to unblinding by more than 30%.

The principle of separating pharmaceuticals from psychotherapy has also become clear. The guidelines limit the subject that pharmaceutical companies must prove to the biochemical response of the drug itself. The accompanying psychological support is being standardized, reduced to supportive care that ensures the patient's physical safety, rather than exploratory psychoanalysis. Psychotherapy intervention, which previously lasted up to 40 hours, is being simplified into a standard protocol of approximately 8 hours, including preparation before administration, monitoring on the day of administration, and follow-up checks.

Risk Evaluation and Mitigation Strategies (REMS) to ensure post-market safety also imposed strict conditions. In medication administration areas within the hospital, at least two certified medical professionals must be on duty, and a system is established where the patient's blood pressure and heart rate are measured every 30 minutes for at least 6 hours. The establishment of a national registry to monitor all patients receiving the medication for 12 months is included as a mandatory requirement to track Hallucinogen Persisting Perception Disorder (HPPD) and cardiovascular adverse reactions.

Implications and Outlook

The new evaluation rules provide a clear clinical compass for biotech companies pursuing the development of new psychedelic drugs. The standardization of evaluation scales and the simplification of psychological support are expected to act as a lever to reduce massive clinical costs. As reliance on therapists decreases, psychedelic administration programs can be implemented in general specialized clinics, improving patient accessibility. It also opens the way for private insurers, who were hesitant to approve combination therapies, to list drugs on the insurance coverage by calculating drug costs and standard care costs separately.

The problem has not been fully resolved. The spatial burden of isolating patients in a designated area for observation for more than 6 hours on the day of administration, along with the deployment of specialized nursing staff, continues to impose heavy operational costs on medical institutions. The risk of cardiac valve fibrosis resulting from 5-HT2B receptor stimulation and blood pressure elevation induced by hallucinogenic effects necessitates continuous monitoring.

Competition with next-generation pipelines is also a key factor to watch. Non-hallucinogenic psychoplastogens, which act on serotonin receptors but do not induce hallucinations, are entering Phase 2 clinical trials. If follow-on drugs that facilitate blinding maintenance and patient management are developed, the initial psychedelic market may face a narrower foothold. Despite federal deregulation, if the Drug Enforcement Administration (DEA) schedule for substance rescheduling is delayed, the risk of slowing the pace of commercialization remains.